

10-31-2002

FORM PTO-1595
1-31-92U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

102266645

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

AVANIR PHARMACEUTICALS,
formerly known as LIDAK PharmaceuticalsAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of Conveyance:

☐ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☒ Other: **Release of Security Interest**

Execution Date: July 31, 2002

2. Name and address of receiving party(ies):

Name: MEDICAL BIOLOGY INSTITUTE
Address: 3550 GENERAL ATOMICS COURT
City: SAN DIEGO State: CA Zip: 92121Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this Document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

07/327,910 07/503,047
07/760,086 08/792,760
08/475,785 08/663,617
08/837,599 60/000,674

B. Patent No.(s)

5,470,714 5,045,320

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Erin O'Brien
Internal Address: **GRAY CARY WARE & FREIDENRICH**
400 Hamilton Avenue
Palo Alto, CA 94301

6. Total number of applications and patents involved: 10

7. Total fee (37 CFR 3.41) \$ 400.00
☒ Enclosed

8. Deposit account number:

Please debit any underpayment or credit any
overpayment to the above deposit account.

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Erin O'Brien

Name of Person Signing

Signature

October 24, 2002

Date

Total number of pages comprising cover sheet: [4]

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

U.S. Patent and Trademark Office
Office of Public Records
Crystal Gateway 4, Room 335
Washington, DC 20231

10/30/2002 LMUELLER 00000219 07327910

01 FC:8021

400.00 OP

Gray Cary\SD\1520400.1
103900-154348PATENT
REEL: 13417 FRAME: 0733

AUG-02-02 15:26 FROM-

nt By: TPIMS;

0137000001,

T-948 P.002/004 F-116

RELEASE OF SECURITY INTEREST

A. AVANIR Pharmaceuticals, a Delaware corporation, formerly known as LIDAK Pharmaceuticals ("AVANIR"), was given a security interest by Medical Biology Institute, a California nonprofit public benefit corporation (the "Institute"), in 14 patents and patent applications (the "Encumbered Patents and Applications") as further described in the attached Exhibit 5A.

B. The security interest was given to AVANIR to secure payment by the Institute of a certain Promissory Note, pursuant to that certain Settlement Agreement and Mutual General Release, dated September 24, 1998, between LIDAK Pharmaceuticals and the Institute (the "Settlement Agreement").

C. Pursuant to Section 3.6 of the Settlement Agreement, the Promissory Note has been forgiven and AVANIR is obligated to terminate and release the security interest in the Encumbered Patents and Applications.

WHEREFORE, AVANIR hereby releases and terminates the security interest in the Encumbered Patents and Applications. AVANIR hereby authorizes the Institute to file with the United States Patent and Trademark Office and with the California Secretary of State and with any other governmental agency as appropriate, evidence that AVANIR has terminated and released its security interest in the Encumbered Patents and Applications.

Dated as of July 31, 2002

AVANIR Pharmaceuticals, formerly known as
LIDAK Pharmaceuticals, a Delaware corporation

By: 

AUG-02-02 15:27 FROM-

int 8y: TPIMS;

T-948 P.003/004 F-116

EXHIBIT 5A
PATENTS AND APPLICATIONS SUBJECT TO SECURITY AGREEMENT
BETWEEN LIDAK PHARMACEUTICAL AND MEDICAL BIOLOGY INSTITUTE

Patent or Application No./DateTitle and/or Description**AMPLIFIED SIGNAL IMMUNOASSAY.**

Chemical and biochemical reactions which are a function of the state of various immunogenic species permit very sensitive immunoassays.

ONE-STEP IMMUNOLOGICAL TEST.

An immunoassay system in which the entire assay is carried out in one step without the sequence of reagent additions and washing required in most current assays. This invention has potential value as a diagnostic assay for home use and in doctor's offices and clinics.

INHIBITION OF NEURO SIGNALS. Certain biochemical compounds are being evaluated as specific binding probes for inhibiting seizures and spasms triggered by the central nervous system.

DNA BLOTTING METHOD. A very high sensitivity method for identifying and transferring specific DNA species. This invention has potential application in DNA research and in the preparation of diagnostic and therapeutic reagents.

SMALL UNILAMELLAR VESICLES. A new immunological reagent and method which potentially provides for rapid, reliable and highly sensitive immunoassays.

LARGE MULTIVALENT ANTIGEN THERAPY. A novel therapeutic method using specially bound multivalent antigens.

NUCLEIC ACID HYBRIDIZATION ASSAY. A hybridization assay for specific DNA and RNA sequences with potential applications in genetic engineering, forensic biochemistry, and implantation therapy.

ONE-STEP IMMUNOASSAY USING A BINARY REPORTER SYSTEM. A novel immunoassay system with potential in domestic and laboratory applications.

AUG-02-02 15:27 FROM-
nt By: TPIMS;

010700001,

T-948 P.004/004 F-116

Patent or Application No./Date

Title and/or Description

CELL ACTIVATION BY IMMOBILIZED
MEMBRANE PROTEINS. A simplified, reliable
immunoassay system having potential value in
domestic and laboratory applications.

METHOD FOR DETERMINING PLASMA-
FREE FATTY ACIDS FOR DISEASE
DETECTION.

MURINE MODEL OF AIDS-LIKE VIRUS
INFECTION.

Technologies Added by Amendment
to License Agreement

EPIDERMAL LANGERHANS CELL MIGRATION
AND FUNCTION TECHNOLOGY.

SYNTHETIC PEPTIDES AS INHIBITORS OF
COMPLEMENT ACTIVATION.

FATTY ACID LEVELS IN PATIENTS AT RISK
FOR ISCHEMIC INSULT.